Tagged with IP

Italy Ipsen’s Stephane Brocker discusses a transformational period for the iconic French mid-cap in recent years, how this has played out in Italy, and emergent trends – such as hybrid digital/in-person physician interactions – that have emerged from the COVID-19 pandemic period. Brocker also touches on Italy’s relevance to the global…

Spain HIPRA is a world-leading animal health company that has launched a record 22 animal vaccines in the last 10 years. During the COVID-19 pandemic, the European company decided to jump into human health with its own vaccine candidate, currently in phase III trials. Carles Fàbrega, managing director of HIPRA’s new…

Hong Kong Having consolidated its position as Asia’s largest biotech fundraising hub – and the world’s second largest – the Hong Kong Stock Exchange (HKEX) listed a total of 34 biotech and healthcare companies in 2021. “[Last year’s listings] made us rank first by number of deals and second by the amount…

APAC The latest pharma news from Southeast Asia, including the Singaporean Health Sciences Authority (HSA) being awarded the highest maturity level in the WHO’s classification of global regulatory authorities, as well as highlights from Indonesia, the Philippines, and Malaysia   Singapore medicines regulator world’s first to achieve highest maturity level in…

Global Two years into his role, Ipsen’s EVP and Chief Medical Officer Prof. Dr. med. Steven Hildemann MD discusses his vision of patient-centricity and how he is leading a medical transformation that puts data-driven insights at the core and aims to make a real difference to both clinical practice and patients’…

UK Oxford Nanopore hogged the UK biotech headlines in 2021, raising GBP 195 million in a single venture capital round – the year’s largest – and scoring a GBP 350 million listing on the London Stock Exchange, according to new data from the UK BioIndustry Association (BIA) and Clarivate. See below…

France French mid-cap pharma Ipsen achieved total sales of EUR 2.869 billion in 2021, a 12.3 percent increase on results from the pandemic-affected 2020 total. The company also announced plans to divest its consumer healthcare business – which currently accounts for around eight percent of total revenues – to fellow French…

Spain Merck’s general manager for Spain, Miguel Fernández Alcalde, speaks about the company’s shift towards becoming a global specialty innovator, what it means for their portfolio, and explains the group’s broad footprint in Spain, where it maintains three manufacturing sites. In addition, Fernández analyses the Spanish pharma market and what he…

Global Drawing on the findings of EY’s recently published life sciences M&A firepower report, EY Global Life Sciences Deals Leader Subin Baral makes the case for big biopharmas to seek out alliances and partnerships as an alternative to M&A and lists ten considerations that these firms should bear in mind if…

Global Speaking from Ipsen’s US headquarters in Cambridge, Massachusetts off the back of a whirlwind first 16 months as the firm’s Chief Business Officer, Philippe-Lopes Fernandes outlines his deal-making philosophy, how the iconic French mid-cap represents a reliable partner for innovative biotechs looking to establish a global reach for their programs,…

Singapore Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of the current regulatory framework for orphan drug registration in four ASEAN countries and what more could be done to improve it.   Regulatory authorities such…

Spain The latest from Spanish pharma, including Rovi’s better-than-expected 2021 results thanks to its Moderna partnership, the approval of Hipra’s COVID-19 IIb clinical trials, Sanifit Therapeutics’ acquisition by Vifor Pharma, and the health technology sector’s request to the administration.   Grifols will use funds from GIC to reduce its debt (The…